Abattis Bioceuticals qualified to trade on OTCQX

OTC Markets Group Inc. (OTCQX: OTCM), operator of Open, Transparent and Connected financial marketplaces, today announced that Abattis Bioceuticals Corp. (CSE: ATT; OTCQX: ATTBF), a specialty biotechnology company, has qualified to trade on OTCQX®, the best marketplace.

Abattis begins trading today on OTCQX under the symbol "ATTBF." U.S. investors can find current financial disclosures and Real-Time Level 2 quotes for the company on www.otcmarkets.com.

"We welcome Abattis to the OTCQX marketplace," said R. Cromwell Coulson, President and CEO of OTC Markets Group. "Abattis joins a growing group of Canadian exchange-listed companies that have chosen to trade on the OTCQX market to provide its investors with transparent trading and convenient access to its news and financials. We wish the company continued success."

"Abattis Bioceuticals is dedicated to providing a high level of transparency to shareholders," said Abattis Bioceuticals Corp. CEO Mike Withrow. "The upgrade to OTCQX provides investors with increased transparency in financial reporting and disclosure and awareness of the company's activities within the botanical drug and cannabis industry and inspires confidence within the investment community."

Troutman Sanders LLP serves as Abattis' Principal American Liaison ("PAL") on OTCQX, responsible for providing professional guidance on OTCQX requirements and U.S. federal securities laws.

Abattis is a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal marijuana markets in North America.


OTC Markets Group Inc.

Posted in: Business / Finance

Tags: ,



The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
You might also like... ×
Mayo Clinic experts move closer to realizing clinical potential of senolytic drugs on aging